Filing Details
- Accession Number:
- 0001209191-21-049763
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-04 18:32:48
- Reporting Period:
- 2021-08-03
- Accepted Time:
- 2021-08-04 18:32:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1858848 | Tenaya Therapeutics Inc. | TNYA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1534264 | Eli Casdin | C/O Tenaya Therapeutics, Inc. 171 Oyster Point Blvd., 5Th Flr. South San Francisco CA 94080 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-03 | 2,374,849 | $0.00 | 2,374,849 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-08-03 | 850,000 | $15.00 | 3,224,849 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-08-03 | 361,969 | $0.00 | 361,969 | No | 4 | C | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2021-08-03 | 2,012,880 | $0.00 | 2,012,880 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2021-08-03 | 361,969 | $0.00 | 361,969 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2021-08-03 | 361,969 | $0.00 | 361,969 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF).
- Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any.
- These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF).
- Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.
Billionaire Hedge Funds
